北大医药(000788) - 2024 Q2 - 季度业绩预告

Financial Performance Forecast - The company expects a net profit of between 83 million and 95 million yuan for the first half of 2024, representing a year-on-year growth of 161.41% to 199.21% compared to 31.75 million yuan in the same period last year[10]. - The net profit after deducting non-recurring gains and losses is projected to be between 83.07 million and 95.07 million yuan, indicating a year-on-year increase of 220.40% to 266.68% from 25.93 million yuan[10]. - Basic earnings per share are expected to be between 0.1393 yuan and 0.1594 yuan, compared to 0.0533 yuan per share in the same period last year[10]. - The performance forecast period is from January 1, 2024, to June 30, 2024[9]. Business Segments Performance - The pharmaceutical industrial segment has seen an increase in key product sales and cost reduction efforts, enhancing profitability year-on-year[4]. - The pharmaceutical distribution segment has experienced a year-on-year increase in revenue from supply chain management services[11]. - The company is focused on enhancing its operational efficiency and profitability through strategic initiatives in its key business segments[4]. Disclosure and Investor Guidance - The company emphasizes that the performance forecast is based on preliminary estimates and will be detailed in the 2024 semi-annual report[12]. - The company assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements[6]. - Investors are advised to make rational decisions and be aware of investment risks[12].